Paolo Tarantino: Do patients with these small triple-negative tumors benefit from chemotherapy?
Paolo Tarantino, Research Fellow presso Dana-Farber Cancer Institute, shared a post on LinkedIn:
“One third of all TNBCs are diagnosed as stage I tumors (≤2 cm). Do patients with these small triple-negative tumors benefit from chemotherapy?
To try answering this question, we conducted a large population-based study, involving >8000 patients in the SEER database and now published on NPJ Breast.
We found excellent (>90%) breast cancer-specific survival in this population, and that most of the benefit of adjuvant chemotherapy is restricted to those with tumors 1-2 cm (pT1c).
Below this threshold, biomarkers able to guide treatment are a huge unmet need. TILs, gene signatures, ctDNA are all great candidates, and may hopefully soon help tailoring treatment and avoiding unnecessary toxicities for our patients.”
